Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutationsInvestigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921 is a potential "first-in-class" cardiovascular AAV gene therapy being developed for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations
Vanotech Appoints Matthew Schiller to Lead Business DevelopmentROCKAWAY, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Vanotech Ltd, a pharmaceutical company devoted to greatly improving the lives of people living with Ophthalmic, central nervous, digestive and endocrine conditions using innovative science that results in breakthrough medicines, announced today that Matthew Schiller has been appointed as Head of Business Development. Mr. Schiller brings extensive leadership experience in biopharma business development and joins Vanotech to lead the Company’s business development operations.
